Erdogar, N. Et Al. 2021. Erlotinib complexation with randomly methylated beta-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY , vol.26 , 797-806.

Erdogar, N., Akkin, S., VARAN, G., & BİLENSOY, E., (2021). Erlotinib complexation with randomly methylated beta-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY , vol.26, 797-806.

Erdogar, NAZLI Et Al. "Erlotinib complexation with randomly methylated beta-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer," PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY , vol.26, 797-806, 2021

Erdogar, NAZLI Et Al. "Erlotinib complexation with randomly methylated beta-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer." PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY , vol.26, pp.797-806, 2021

Erdogar, N. Et Al. (2021) . "Erlotinib complexation with randomly methylated beta-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer." PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY , vol.26, pp.797-806.

@article{article, author={NAZLI ERDOĞDU Et Al. }, title={Erlotinib complexation with randomly methylated beta-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer}, journal={PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY}, year=2021, pages={797-806} }